Ongoing Collaborations - Pre-clinical Studies:
| Institution | PI Name | Model | # of Subjects (Samples) | Progress |
| FDA (CDRH) | Dr. Peter Goering | Chromium, Gentamicin, Mercuric chloride | 60 (250) | To be submitted |
| Dr. Ron Brown | ||||
| Dr. Peter Goering | Subclinical renal injury in rats | 120 (192) | To be submitted | |
| Dr. Ron Brown | ||||
| FDA (CDER) | Dr. Parvaneh Esparandi | Age-dependent Gentamicin renal toxicity | 60 (240) | To be submitted |
| Age-dependent Cisplatin renal toxicity | 60 (240) | To be submitted | ||
| Midwestern University, Illinois | Dr. Walter Prozialeck | Cadmium | 50 (600) | Accepted-pending revision |
| University of Sherbrooke, Quebec, Canada | Dr. Olivier Lesur | LPS/endotoxin | 20 (200) | To be submitted |
| Washington Unversity, Missouri | Dr. Evan Khrasch | Sevoflurane | 16 (40) | Preliminary Results |
| University of Lousiana at Monroe | Dr. Hari Mehendale | Rat model of diabetic nephropathy | 24 (80) | Preliminary Results |
| Texas A&M University | Dr. Alan Parrish | Aging-associated renal failure | 36 (144) | To be submitted |
| University of Mexico | Dr. Normal Bobadilla | Cyclosporine | 12 (40) | AJP, 2007;292(1):F131-F139 |
| Oregon Health & Science University | Dr. Sharon Anderson | Hypertonic saline-induced AKI in hemorrhagic shock model | 24 (300) | Experiments ongoing |
| Groningen University, Netherlands | Dr. Van Timmeren | Protein Overload | 40 (250) | AJP 2006;291(2):F456-F464 |
| Dr. Andrea Krammer | Adriamycin nephrosis | 40 (250) | To be submitted | |
| Dr. Martin De Borst | Ren2 transgenic model | 25 (150) | AJP 2007;292(1):F313-F320 | |
| Dr. Theo Shuurs | Brain dead donor kidney | 12 (40) | To be submitted | |
| Merck | Dr. Josef Ozer | (200) | To be submitted | |
| Pfizer | Dr. Rabih Slim | (200) | Completed | |
| Glaxo Smithkline | Dr. Alan Olzinski | (150) | To be submitted | |
| Novartis | Dr. Gerard Maurer | (2000) | To be submitted | |
| Cubist | Dr. Rick Oleson | (200) | Completed |
Ongoing Collaborations - Clinical Studies:
| Institution | PI Name | Model | # of Subjects (Samples) | Progress |
| FDA (CDER) | Dr. Peter Goering | Gentamicin-induced renal injury in clinical studies | Experiments ongoing | |
| Dr. Ron Brown | ||||
| FDA (CDER)/Children’s Hosptial, DC | Dr. Ron Brown | Pediatric renal injury | Experiments ongoing | |
| Umea University, Sweden | Dr. Gunar Nordberg | Human Cadmium exposure | (750) | Sending samples |
| Shanghai University, China | Dr. Taiyi Jin | |||
| Brigham and Women’s Hospital | Drs. Waikar/Vaidya/Bonventre | Intracavitary Cisplatin (Mesothelioma) | 80 (560) | IRB approved |
| Cisplatin for Germ Cell CA | 100 (1000) | IRB approved | ||
| Contrast: Cardiac Cath | 100 (400) | Ongoing | ||
| Gentamicin | 40 (200) | Ongoing | ||
| AAA repair | 100 (700) | Ongoing | ||
| Kidney Biopsies | 100 (100) | Ongoing | ||
| Maine Medical Center | Dr. J. Himmelfarb | T=0 transplant biopsies | 40 (160) | Ongoing |
| Hosp Clinic, Barcelona | Dr. Gines | Cirrhotics | 95 (580) | IRB approved |
| Dr. Marie-Noëlle Pépin | ||||
| Beth Israel Deaconess | Dr. F. Epstein | Cross-sectional AKI | 61 (77) | Data analysis |
| Texas Children’s Hospital | Dr. S. Goldstein | Cardiopulmonary bypass | 80 (320) | Ongoing |
| Cincinnati Children’s Hospital | Dr. Devarajan | Cardiopulmonary bypass | 40 (280) | Kim-1, NAG, MMP-9 |
| Charitas-St. Eliz. Medical Center, Boston | Dr. Jaber | Cardiopulmonary bypass | 100 (412) | Ongoing |
| Dr. Orfeas | ||||
| Charitas-St. Eliz. Medical Center, Boston | Dr. Jaber | Cross-sectional AKI | 200 (209) | JASN. 2007;In Press |
| Dr. Orfeas | ||||
| Christ Church School of Medicine, New Zealand | Dr. Endre | Decompensated cardiac failure | 100 (500) | Ongoing |
| Dr. Westhuzen | ||||
| Geisinger Medical Center, Pennsylvania | Ping Zhang | Clinical/Pathological correlations | 200 | Manuscript submitted |
| Novartis | Dr. Gerard Maurer | (2000) | Experiments ongoing |
